(PharmaNewsWire.Com, April 03, 2020 ) The pharmaceutical excipients market is projected to reach USD 9.7 billion by 2025 from USD 6.9 billion in 2019, at a CAGR of 5.8%. Factors such as the growing pharmaceuticals industry coupled with advancements in functional excipients, rising adoption of orphan drugs, and increasing uptake of biopharmaceuticals, are driving the market for pharmaceutical excipients. The emergence of multifunctional excipients, shifting the focus of pharmaceutical manufacturing to emerging markets, and the growing biosimilars industry also present significant growth opportunities for market players.
By functionality, the fillers and diluents segment is expected to account for the largest share of the pharmaceutical excipients market in 2019
The fillers & diluents segment accounted for the largest share of the pharmaceutical excipients market in 2018. This market segment is expected to grow due to the increased use of fillers and diluents in the development and production of solid oral drugs. Oral formulations account for a majority share in the pharmaceutical industry, and as these formulations require fillers and diluents the most, this segment automatically has the majority share of the pharmaceutical excipients market.
By formulation, the oral formulations segment is estimated to account for the largest share of this market in 2019
Based on formulation, the pharmaceutical excipients market is segmented into oral, topical, parenteral, and other formulations. In 2018, oral formulations accounted for a major share of the pharmaceutical excipients market, mainly because oral formulations are the most common route of drug delivery. Owing to the shrinking pipeline of new chemical entities (NCEs), companies are increasingly focusing on developing orally disintegrating tablets (ODTs) and other novel methods of oral drug delivery. There is also a growing trend towards sachet formulations.
The global pharmaceutical excipients market is highly fragmented as none of the market players held a market share of more than 15%. The top ten players account for more than half of the total market share, while several other global and regional market players account for the remaining share.
The leading market players are based across developed countries such as the US, Germany, France, the UK, and Ireland. Various small and medium-sized players operating in both developed and emerging markets are making this a highly competitive market. On the other hand, dominant market players have numerous advantages such as stronger marketing & distribution networks, greater budgets for R&D, and better brand recognition. The market also shows the presence of numerous small players operating at the global as well as the regional levels. Companies are increasing their focus on R&D to add innovative products to their portfolios, which, in turn, helps them strengthen their market presence. In addition to this, the lucrative growth opportunities in the relatively untapped APAC market are encouraging market players to strengthen their presence in this region.
The key players in the global pharmaceutical excipients market are Ashland (US), BASF (Germany), DuPont (US), Roquette (France), Evonik Industries (Germany), Associated British Foods (UK), Archer Daniels Midland Company (US), Lubrizol (US), and Croda International (UK).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
